Prevalence of metabolic syndrome and associated behavioural factors in Tunisian adolescents

Abstracts 173 with prolactinomas as well as weight loss associated with dopaminergic treatment. This work aims to assess the prevalence of obesity in patients with macroprolactinomas, before and after treatment with bromocriptin, and identify some determinants of weight variation during follow-up. Methods: Medical records of patients with macroprolactinomas, treated with bromocriptin for ≥2 years, were retrospectively reviewed. Analyzed: tumor size; prolactin; anthropometric data; persistent hypogonadism and bromocriptin doses. Statistical analyses:SPSS(21). Results: There were 87 eligible patients, 53 women, with 40.67 ± 15.44years. Initial obesity prevalence was 41.3% [class I:24,1%; class II:11,5%; class III:5,7%]. One third of the patients (n = 29) had persistent hypogonadism, although these didn’t present initial higher prolactin levels or an association with obesity (p > 0.05). The median bromocriptin cumulative dose was 15432.78 (1825–81395)mg, over 8.04 ± 5.56years. Most patients (89.7%) normalized prolactin levels. After treatment more than half of the patients (n = 47) had lost weight, and there was a global BMI reduction (29.0 ± 5.0 vs. 28.3 ± 4.9kg/m2; p = 0.014). Final obesity prevalence was 30.1% [class I:20.5%, class II:5.5%; class III:4.1%]. BMI wasn’t correlated with prolactin or bromocriptin cumulative dose (p > 0.05), although prolactin normalization quadrupled the odds of losing weight (OR:4.65; p = 0.031). Conclusion: There was a high prevalence of obesity in patients with macroprolactinomas and a significant weight reduction after treatment with bromocriptin. Despite the main mechanisms remain undetermined, patients that achieved normal prolactin levels were more likely to lost weight. These findings reinforced the metabolic importance of an appropriate treatment of patients with macroprolactinoma, particularly the obese one.